SF3B6 and breast carcinoma: Previous studies of SF3B6 in tumors have been limited to PDAC, breast cancer, and NSCLC (Siebring-van Olst et al., 2017; Wu et al., 2019; Li J. et al., 2021; Peng et al., 2022).